General Information of Drug (ID: DMQC168)

Drug Name
3-(1,3 dodecadiynyl)-6-oxiranebutanoic acid Drug Info
Synonyms
4-[3-(Dodeca-1,3-diyn-1-yl)oxiran-2-yl]butanoic acid; CHEMBL483819; FA(18:4)(Ep,cyclo); GTPL2958; LMFA01070030; BDBM50292404; 5,6-Epoxyoctadeca-7,9-diynoic acid; 5,6-epoxy-7,9-octadecadiynoic acid; compound 9a [Patil et al, 1989]; 4-[3-(dodeca-1,3-diyn-1-yl)oxiran-2-yl]butanoic; compound 9a (Patil et al., 1989)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
14309407
TTD Drug ID
DMQC168

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug(s) Targeting HMG-CoA reductase (HMGCR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [2]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [3]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [4]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [5]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [6]
Fluvastatin DM4MDJY Arteriosclerosis BD40 Approved [3]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [7]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [3]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [8]
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [1]

References

1 Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989).
2 A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
3 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
4 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
5 Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
6 New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
7 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
8 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.